Drug intelligence / Profile preview

MS14

Development stage: Phase 2
Modality: Small Molecules
Administration: Oral

Overview

MS14 is a herbal-marine compound with anti-inflammatory and immunomodulatory properties used in the treatment of multiple sclerosis (MS). It works by reducing inflammatory cytokines such as TNFα and IL-1β, which helps decrease damage to the protective coating around nerve cells. In clinical studies, MS14 has shown efficacy in reducing clinical signs of MS, improving physical activity, walking function, and reducing fatigue in patients.

Targets

TNFA (Tumor necrosis factor alpha (soluble))IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on MS14.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MS14.

Explore the full profile